(Vaprisol®): a nonpeptide antagonist of V1A & V2 vasopressin receptors. FDA approved for euvolemic and hypervolemic moderate-to-severe hyponatremia in hospitalized patients (NB: severe symptoms of seizures, coma, delirium…warrants aggressive treatment with hypertonic saline 1)).